Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.68 CAD
Change Today +0.02 / 3.03%
Volume 9.1K
AEZ On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 9:56 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

aeterna zentaris inc (AEZ) Snapshot

Open
C$0.67
Previous Close
C$0.66
Day High
C$0.68
Day Low
C$0.67
52 Week High
09/2/14 - C$1.68
52 Week Low
11/19/14 - C$0.55
Market Cap
44.5M
Average Volume 10 Days
80.5K
EPS TTM
C$-0.25
Shares Outstanding
65.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETERNA ZENTARIS INC (AEZ)

Related News

No related news articles were found.

aeterna zentaris inc (AEZ) Related Businessweek News

No Related Businessweek News Found

aeterna zentaris inc (AEZ) Details

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company’s product pipeline includes MACRILEN, which completed the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer. It is also developing two oncology compounds, including an Erk inhibitor and luteinizing hormone-releasing hormone-disorazol Z product candidates, which are in pre-clinical development. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Quebec City, Canada.

56 Employees
Last Reported Date: 03/17/15
Founded in 1991

aeterna zentaris inc (AEZ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $475.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $309.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Chief Scientific Officer, Chief Medical Offic...
Total Annual Compensation: $265.8K
Vice President of Finance
Total Annual Compensation: $240.0K
Compensation as of Fiscal Year 2014.

aeterna zentaris inc (AEZ) Key Developments

Aeterna Zentaris Inc. Proposes Amendments to the Articles

Aeterna Zentaris Inc. proposed the filing of articles of amendment to consolidate the issued and outstanding common shares of the corporation on the basis, at the annual and special meeting of shareholders of the company to be held on May 8, 2015.

Aeterna Zentaris Inc. Announces Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015

Aeterna Zentaris Inc. announced audited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $10,947,000 against $7,972,000 a year ago. Income before income taxes was $4,106,000 against loss before income tax of $10,596,000 a year ago. Net income from continuing operations was $3,995,000 or $0.06 per basic and diluted share against net loss from continuing operations of $10,596,000 or $0.28 per basic and diluted share a year ago. Net income was $4,153,000 or $0.06 per basic and diluted share against net loss of $8,243,000 or $0.22 per basic and diluted share a year ago. Cash used in operating activities from continuing operations was $8,676,000 against $6,184,000 a year ago. Total revenue was $11,000. For the year, the company reported loss from operations of $37,395,000 against $27,476,000 a year ago. Loss before income taxes was $17,076,000 against $27,240,000 a year ago. Net income from continuing operations was $17,187,000 or $0.29 per basic and diluted share against $27,240,000 or $0.92 per basic and diluted share a year ago. Net loss was $16,564,000 or $0.28 per basic and diluted share against net income of $6,815,000 or $0.24 per basic and diluted share a year ago. Cash used in operating activities from continuing operations was $30,787,000 against $30,131,000 a year ago. Net cash used in operating activities was $31,082,000 against $19,984,000 a year ago. Purchase of property, plant and equipment was $127,000 against $85,000 a year ago. Total revenue was $11,000. For the year ended December 31, 2015, the company expects net cash used in operating activities to range from $33 million to $35 million, mainly as the company continues to invest in ZoptEC phase 3 program and related sub-studies, as it carry out initiatives related to the co-promotion of EstroGel and as continue making severance payments in connection with the resource optimization program. This guidance may vary significantly in future periods, most notably in light of ongoing business development initiatives. Having entered into the co-promotion agreement with ascend, the company expects to generate sales commission revenue in 2015 pursuant to the initiation of sales coverage in the agreed-upon territories and as the company begins to exceed certain minimum agreed-upon thresholds. Further, having entered into the master collaboration agreement, TTA and LA with Sinopharm, the company will commence recognition of the amortization of deferred revenues related to the transfer fee. R&D costs will range between $21 million and $23 million. R&D costs are expected to decrease in 2015, as compared to 2014, mainly as a result of the implementation of resource optimization program.

Aeterna Zentaris Mulls Acquisitions

Aeterna Zentaris Inc. (TSX:AEZ) is seeking acquisitions. David Dodd, Chairman and Chief Executive Officer of Aeterna Zentaris said in Aeterna Zentaris fourth quarter and full-year 2014 financial and operating results, "We are continuing to evaluate potential in-licensing and/or acquisition opportunities, as well as additional co-promotional arrangements related to marketed products, in order to grow our commercial activities.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEZ:CN C$0.68 CAD +0.02

AEZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEZ.
View Industry Companies
 

Industry Analysis

AEZ

Industry Average

Valuation AEZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,158.3x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,198.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETERNA ZENTARIS INC, please visit www.aezsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.